About CareDx
What CareDx is building
Company culture
Innovation
Patient Centricity
Funding rounds
Company type
CareDx news and updates
CareDx, Inc. has issues with potential breaches of fiduciary duties
An investigation was announced for current long-term investors in shares of CareDx, Inc (NASDAQ: CDNA) concerning potential breaches of fiduciary duties by certain directors and officers of CareDx, Inc.
Sep 13, 2022 | openpr.comCareDx, Inc. hired Abhishek Jain as CFO on Sep 7th 22'.
CareDx appointed Abhishek Jain as CFO effective Sept. 7.
Sep 9, 2022 | genomeweb.comCareDx, Inc. launched environmental, social and governance report on Jun 21st 22'.
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the release of its first environmental, social and governance (ESG) report.
Jun 21, 2022 | businesswire.comCareDx, Inc. launched XenoSure donor-derived cell-free DNA and XenoMap on Mar 23rd 22'.
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the availability of XenoSure™ donor-derived cell-free DNA (dd-cfDNA) and XenoMap™ gene-expression profiling for investigational use in xenotransplantation research and post-xenotransplant clinical monitoring.
Jan 1, 2022 | kulr8.comCareDx, Inc. partnered with HeartBrothers Foundation on Mar 29th 22'.
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is partnering with the HeartBrothers Foundation as a corporate member and also hosting a patient education webinar together.
Jan 1, 2022 | stockhouse.comCareDx, Inc. partnered with European Society for Organ Transplant on Mar 30th 22'.
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is partnering with the European Society for Organ Transplantation (ESOT) to provide education for its membership on the clinical evidence supporting the use of donor-derived cell-free DNA (dd-cfDNA) to monitor transplanted organ health.
Jan 1, 2022 | globenewswire.comCareDx, Inc. launched commercial product on Jan 1st 05'.
In 2005, CareDx launched its first commercial product, AlloMap Heart, representing one of the first tests of its kind, a blood test to non-invasively monitor organ health in heart transplant recipients.
Jan 1, 2022 | streetinsider.comPhan leaves CareDx, Inc. as Senior Vice President of Lab Services and Medical Director
Dr. Phan joins Aspira from CareDx where he served as Senior Vice President of Lab Services and Medical Director.
Jan 1, 2022 | stockhouse.comCareDx, Inc. has issues with violating two of its patents covering technology
Natera Inc., a maker of DNA analysis tests, sued competitor CareDx Inc. for violating two of its patents covering technology for assessing the likelihood of an organ transplant rejection, deepening a yearslong intellectual property dispute between the two rivals.
Jan 1, 2022 | bloomberglaw.comCareDx, Inc. has issues with violations of the Securities Exchange Act of 1934
The CareDx class action lawsuit charges CareDx and certain of its top executive officers with violations of the Securities Exchange Act of 1934.
Jan 1, 2022 | businesswire.comGlancy Prongay & Murray LLP acquires CareDx, Inc.
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA ) common stock between February 24, 2021 and May 5, 2022, inclusive (the “Class Period”).
Jan 1, 2022 | businesswire.comCareDx, Inc. has issues with failing to disclose material information during the Class Period, violating federal securities laws
CareDx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
Jan 1, 2022 | businesswire.comBragar Eagel & Squire PC files suit against CareDx, Inc.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired CareDx securities between February 24, 2021 and May 5, 2022, both dates inclusive (the “Class Period”).
Jan 1, 2022 | businesswire.comCareDx, Inc. has issues with alleged securities fraud
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of CareDx investors who were adversely affected by alleged securities fraud.
Jan 1, 2022 | prnewswire.comBronstein, Gewirtz & Grossman, LLC files suit against CareDx, Inc.
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired CareDx securities between February 24, 2021, and May 5, 2022, (the "Class Period").
Jan 1, 2022 | wbrc.comCareDx, Inc. has issues with securities fraud or other unlawful business practices
The investigation concerns whether CareDx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Jan 1, 2022 | globenewswire.comCareDx, Inc. filed suit against Natera, Inc. on Apr 10th 19'.
South San Francisco-based CareDx, a precision medicine company serving transplant patients, sued Austin, Texas-based Natera in 2019 for false advertising of its product and likening it to CareDx’s product.
Jan 1, 2020 | medcitynews.comCharles Schwab Investment Management, Inc. invests into CareDx, Inc.
The California-based Charles Schwab Investment Management has invested 0% in CareDx, Inc (NASDAQ:CDNA).
Jan 1, 2019 | lampnews.comCareDx, Inc. launched iBox validation study on Sep 23rd 19'.
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announces that the iBox validation study from the Paris Transplant Group has been published in the British Medical Journal (BMJ).
Jan 1, 2019 | globenewswire.comNorthern Trust Company invests into CareDx, Inc.
Northern Trust Corporation has invested 0% of its capital in CareDx, Inc (NASDAQ:CDNA).
Jan 1, 2018 | enbulletin.comHorizon Discovery Group plc partners with CareDx, Inc.
Horizon Discovery Group PLC (LON:HZD) says its continued collaboration with CareDx Inc validates its model.
Jan 1, 2016 | proactiveinvestors.com.au